Answers are grounded in this paper and cite their sources.
// Eleni Zografos 1 , Flora Zagouri 2 , Despoina Kalapanida 2 , Roubini Zakopoulou 2 , Anastasios Kyriazoglou 2 , Kleoniki Apostolidou 2 , Maria Gazouli 1 and Meletios-Athanasios Dimopoulos 2 1 Department of Basic Medical Sciences, Laboratory of Biology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece 2 Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece Correspondence to: Eleni Zografos, email: el_zogra@hotmail.com Keywords: breast cancer; microRNAs; prognosis; biomarkers Received: August 07, 2019 Accepted: October 26, 2019 Published: December 24, 2019 ABSTRACT MicroRNAs (miRNAs) have been found to play an important role in breast cancer, functioning either as potential oncogenes or tumor suppressor genes, but their role in the prognosis of patients remains unclear. The aim of the present review study is to highlight recent preclinical and clinical studies performed on both circulating and tissue-specific miRNAs and their potential role as prognostic markers in breast cancer. We systematically searched the PubMed database to explore the prognostic value of miRNAs in breast cancer. After performing the literature search and review, 117 eligible studies were identified. We found that 110 aberrantly expressed miRNAs have been associated with prognosis in breast cancer. In conclusion, the collective data presented in this review indicate that miRNAs could serve as novel prognostic tools in breast cancer, while the clinical application of these findings has yet to be verified.
No takes yet. Share an insight, caveat, or question.
Zografos et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: